KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Resmed (RMD) EBT (2016 - 2025)

Resmed's EBT history spans 17 years, with the latest figure at $496.1 million for Q4 2025.

  • For Q4 2025, EBT rose 18.6% year-over-year to $496.1 million; the TTM value through Dec 2025 reached $1.8 billion, up 18.48%, while the annual FY2025 figure was $1.7 billion, 32.64% up from the prior year.
  • EBT reached $496.1 million in Q4 2025 per RMD's latest filing, up from $446.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $496.1 million in Q4 2025 to a low of $218.0 million in Q1 2021.
  • Average EBT over 5 years is $320.2 million, with a median of $275.2 million recorded in 2022.
  • Peak YoY movement for EBT: decreased 5.2% in 2023, then surged 61.23% in 2024.
  • A 5-year view of EBT shows it stood at $237.3 million in 2021, then increased by 15.34% to $273.7 million in 2022, then dropped by 5.2% to $259.5 million in 2023, then skyrocketed by 61.23% to $418.3 million in 2024, then grew by 18.6% to $496.1 million in 2025.
  • Per Business Quant, the three most recent readings for RMD's EBT are $496.1 million (Q4 2025), $446.8 million (Q3 2025), and $458.1 million (Q2 2025).